Halozyme Therapeutics Inc: Corporate and Strategic Assessment Report - Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Published Date: June 2008 Published By: Datamonitor Page Count: 44 Order Code: R313-34257 $495.00   Online Download $990.00   Global Site License   Questions About This Report E-mail a Colleague Printable Page Fax Your Order Description Table of Contents Search Inside this Report Similar Products Introduction Halozyme is a biopharmaceutical company specialized in the development and commercialization of products based on recombinant hyaluronidase formulation for the treatment of diseases in the areas of oncology and dermatology. The company has proprietary technology, Enhanze. Halozyme entered into an agreement with Roche for developing enzymes using Enhanze technology. Scope Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies Highlights Halozyme is developing several therapeutics and drug delivery platform based on its expertise in recombinant human hyaluronidase enzymes. The company has entered into ageements with Baxter, Cook Ob/Gyn, MediCult, and MidAtlantic Diagnostics, for the worldwide distribution of its products. Halozyme recognized revenues from the year 2005 only. Its revenues increased from $0.13 million in 2005 to $0.34 million in 2006. The growth was primarily attributable to the revenues from Cumulase sales and Hylenex royalties. In addition, the company received license fee and collaboration revenues. Between 2006 and 2010, Halozyme's total revenues are expected to grow at a CAGR of 157% from $1 million to $39 million. Payments under partnership agreements for Enhanze technology, and increasing Cumulase sales and Hylenex royalties wouldlikely contribute majority of the company's revenue growth during 2006-2010. Reasons to Purchase Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization Similar Products • Clinical Cell Culture Limited Product Pipeline Analysis Published Aug 2008 by Global Markets Direct • Omrix Biopharmaceuticals, Inc. Product Pipeline Analysis Published Aug 2008 by Global Markets Direct • Novo Nordisk AS Product Pipeline Analysis Published Aug 2008 by Global Markets Direct • Ayanda Biosystems S.A. Product Pipeline Analysis Published Aug 2008 by Global Markets Direct • Targeted Diagnostics & Therapeutics, Inc. Product Pipeline Analysis Published Aug 2008 by Global Markets Direct • Sequenom, Inc. Product Pipeline Analysis Published Aug 2008 by Global Markets Direct • Qiagen N.V. Product Pipeline Analysis Published Aug 2008 by Global Markets Direct • DNAPrint Genomics, Inc. Product Pipeline Analysis Published Aug 2008 by Global Markets Direct • Orion Genomics Product Pipeline Analysis Published Aug 2008 by Global Markets Direct • Tissue Repair Company Product Pipeline Analysis Published Aug 2008 by Global Markets Direct